Please assess the completion status of the following clinical trial:

Trial Title: BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects at least 18 years of age~2. Constipated, defined by the following adapted ROME II definition~   Fewer than 3 spontaneous defecations per week and at least one of the following symptoms for at least 12 weeks (which need not be consecutive) in the preceding 12 months:~  * Straining during \> 25% of defecations~  * Lumpy or hard stools in \> 25% of defecations~  * Sensation of incomplete evacuation for \> 25% of defecations~3. If female, and of child-bearing potential, is using an acceptable form of birth control~4. Negative serum pregnancy test at screening, if applicable~5. In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study~Exclusion Criteria:~1. Report loose (mushy) or water stools in the absence of laxative use for more than 25% of BMs during the 12 weeks before Visit 1~2. Meet the Rome II criteria for Irritable Bowel Syndrome.~3. Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon~4. Subjects who have had major surgery 30 days before Visit 1; appendectomy or cholecystectomy 60 days before Visit 1; abdominal, pelvic, or retroperitoneal surgery 6 months before Visit 1; bariatric surgery or surgery to remove a segment of the GI tract at any time before Visit 1~5. Subjects with hypothyroidism that is being treated and for which the dose of thyroid hormone has not been stable for at least 6 weeks at the time of Visit 1~6. Subjects taking laxatives, enemas or prokinetic agents that refuse to discontinue these treatments from Visit 1 until after completion of the study~7. Subjects who are pregnant or lactating, or intend to become pregnant during the study~8. Subjects of childbearing potential who refuse a pregnancy test~9. Subjects who are allergic to any study medication component~10. Subjects taking narcotic analgesics or other medications known to cause constipation~11. Subjects with clinically significant cardiac abnormalities identified at the Visit 1 ECG~12. Subjects with clinically significant laboratory abnormalities, deemed as a potential safety issue by the Investigator~13. Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures~14. Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days~15. Subjects with an active history of drug or alcohol abuse~16. Subjects have been hospitalized for a psychiatric condition or have made a suicide attempt during the 2 years before Visit 1~17. Subjects who withdraw consent at any time prior to completion of Visit 1 procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BLI400 Laxative (Type: EXPERIMENTAL): BLI400 Laxative
- Placebo (Type: PLACEBO_COMPARATOR): BLI400 placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete